Michael Hofman: Prognostic Power of PSMA PET from the Updated PROMISE Large International Registry
Michael Hofman, Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC) at Peter MacCallum Cancer Centre, posted on X:
“Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score.
Data across initial stage, biochemical recurrence, “non-metastatic” castration-resistant, mSPC, MCRPC!!
Just out in European Association of Urology.”
Title: Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
Authors: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, Laya Rahbar Nikoukar, Michael Schäfers, Sebastian Hoberück, Matthias Miederer, Tobias Hölscher, Sazan Rasul, Marcin Miszczyk, Francesco Lanfranchi, Matteo Bauckneht, Christian H. Pfob, Felix Kind, Karolien Goffin, Anika Hüsing, Claudia Kesch, Ken Herrmann, Martin Stuschke, Andrei Gafita, Wolfgang P. Fendler
Read The Full Article at European Urology.
More posts featuring Michael Hofman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023